Viridian Therapeutics Inc...
(VRDN)
undefined
undefined%
At close: undefined
Viridian Therapeutics Inc. Analyst Ratings
Total Analysts
12
Consensus Rating
Buy
Price Target
34
Upside
76.07
Ratings History
| Analyst | Firm | Rating | Action | Price Target | Date |
Derek Archila (0.55)
| Wells Fargo | Hold | Downgrades | 27 | Dec 19, 2024 |
Gregory Renza (0)
| RBC Capital | Buy | Maintains | 44 47 | Dec 17, 2024 |
Douglas Tsao (0)
| HC Wainwright & Co. | Buy | Reiterates | 34 34 | Dec 17, 2024 |
Trade Smarter, Not Harder
Cut through market noise with actionable insights that actually help you make confident investment decisions. No more endless research or gut-based guessing.
- Unlimited access to all data and tools
- Unlimited access to all data and tools, giving you the edge over everyone else in the market.
- Realtime Options Data
- Instant access to live options data to spot opportunities and trade with precision before the market moves.
- Top Wallstreet Analyst Ratings
- Follow ratings from the best analysts on Wall Street to stay ahead.
- Up to 30 years financial history
- We deliver premium Wall Street data with top-tier accuracy and up to 30 years of history.
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.